Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- CD 244 48 2B SLAMF 4 IgC 2 Cys 22 HEK 293 NKR 2B4 SHP1 SHP2
- Product Overview:
2B4, also known as CD244, is a cell surface receptor and a member of the signaling lymphocytic activation molecule (SLAM) receptor family (SLAMF).{54463} It is comprised of an extracellular domain containing immunoglobulin (Ig) variable-like (IgV) and Ig constant 2-like (IgC2) motifs and several glycosylation sites, a membrane-spanning region, and a cytoplasmic domain containing serine, tyrosine, and threonine phosphorylation sites.{54464} It is expressed on natural killer (NK) cells, certain T cells, monocytes, basophils, and eosinophils. 2B4 has an activating role when the adapter protein SLAM-associated protein (SAP) is present and bound to intracellular tyrosine-based switch motifs (ITSM) on the cytoplasmic domain.{54463} When SAP is absent, SHP-1, SHP-2, SHIP-1, or CsK are able to bind, which leads to inhibitory signaling. 2B4 has cis- and trans-interactions with the cell surface receptor CD48 during the initiation and continuation of allergic reactions. It has a complex role in cancer, with male, but not female, CD244-/- mice rejecting tumor cells in a xenograft model, however, its role is primarily inhibitory in tumor-associated immune cells.{54464} The expression of CD244 is decreased in NK cells from patients with multiple myeloma or systemic lupus erythematosus (SLE).{54463} 2B4 is associated with X-linked lymphoproliferative disease (XLPD), which is characterized by a mutation in SAP that prevents it from binding to 2B4.{54465} Cayman’s 2B4/CD244 Extracellular Domain (human, recombinant) protein can be used for ELISA. This protein consists of 211 amino acids, has a calculated molecular weight of 23.8 kDa, and a predicted N-terminus of Cys22 after signal peptide cleavage. By SDS-PAGE, under reducing conditions, the apparent molecular mass of the protein is approximately 45-50 kDa due to glycosylation.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.